Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Novo Nordisk licenses EPGN-696 from Epigen

May 25, 2018

VFMCRP and Cara sign development and commercialization agreement for CR-845

May 23, 2018

FDA approves Lokelma for hyperkalemia

May 22, 2018

Bayer patents new vasopressin V1A and V2 receptor antagonists

May 17, 2018

Dimerix announces plans for phase II trials with DMX-200 in chronic kidney disease

May 16, 2018

Promising in vivo results for EP-055, a potential nonhormonal male contraceptive

May 11, 2018

Astellas licenses rights to Aquinox's rosiptor in Japan and Asia-Pacific countries

May 10, 2018

FDA clears Palladio to begin phase II study of lixivaptan in ADPKD

May 9, 2018

FDA approves Myrbetriq in combination with solifenacin for overactive bladder

May 8, 2018

Novel farnesoid X receptor agonists described by Enanta Pharmaceuticals

April 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...